Corticosteroids in Community-Acquired Pneumonia
Corticosteroids should be administered to hospitalized adults with severe community-acquired pneumonia at a dose of 200 mg IV hydrocortisone daily (or equivalent) for 5-7 days, with benefits most pronounced in ICU-level severity, but should be avoided in influenza pneumonia.
Patient Selection Algorithm
Give Corticosteroids:
- Severe CAP requiring ICU admission 1, 2
- Patients with respiratory failure (PaO2/FiO2 < 250 mmHg or requiring mechanical ventilation)
- Hemodynamic instability requiring vasopressors
- Risk of ARDS development
Do NOT Give Corticosteroids:
- Influenza pneumonia (associated with increased mortality, OR 3.06) 1
- Mild-to-moderate CAP not requiring ICU care 1
- Aspiration pneumonia 3
- Myelosuppression 3
Recommended Dosing Regimen
The most robust evidence comes from the 2023 CAPE COD trial 2, which demonstrated a 5.7 percentage point absolute mortality reduction (6.2% vs 11.9%, P=0.006):
Preferred Regimen:
- Hydrocortisone 200 mg IV daily for 4-7 days based on clinical improvement
- Followed by tapering over total duration of 8-14 days
- Alternative: Prednisone, methylprednisolone, or dexamethasone at equivalent doses (< 400 mg hydrocortisone-equivalent daily) 1
Optimal dose-response analysis suggests approximately 6 mg dexamethasone equivalent for 7 days provides maximal mortality benefit (RR 0.44) 4.
Evidence Supporting Use
The 2018 SCCM/ESICM guidelines 1 provide moderate-quality evidence that corticosteroids in hospitalized CAP patients:
- Reduce mortality (RR 0.67, most pronounced in severe pneumonia)
- Decrease mechanical ventilation need (RR 0.45)
- Prevent ARDS (RR 0.24)
- Shorten hospital stay by approximately 3 days
The 2024 American Thoracic Society ARDS guidelines 5 further support corticosteroid use, showing probable mortality reduction (RR 0.84) and decreased mechanical ventilation duration (4 days less).
Most recent high-quality evidence from the 2023 CAPE COD trial 2 in ICU patients with severe CAP demonstrated:
- 28-day mortality: 6.2% (hydrocortisone) vs 11.9% (placebo)
- Reduced intubation: 18.0% vs 29.5% among non-ventilated patients
- Reduced vasopressor initiation: 15.3% vs 25.0%
Severity Stratification Matters
The benefit is severity-dependent. Meta-analyses consistently show mortality reduction in severe CAP but not in mild-to-moderate disease 4, 6. The 2019 IDSA/ATS guidelines 7 specifically recommend corticosteroids only for severe CAP (conditional recommendation, moderate quality).
Safety Profile
Expected adverse effects:
- Hyperglycemia requiring insulin (RR 1.49-1.76) - most common complication 1, 4, 6
- No significant increase in secondary infections (RR 0.97) 6
- No increase in gastrointestinal bleeding 5
Monitor glucose closely during first week of treatment 2.
Critical Caveats
Influenza pneumonia is an absolute exception. Observational data show tripled mortality risk (OR 3.06) with corticosteroids in influenza, likely due to suppression of innate immunity critical for viral defense 1, 7. The 2019 IDSA/ATS guidelines explicitly recommend against routine corticosteroid use in severe influenza pneumonia 7.
Timing matters: Initiate corticosteroids early in severe CAP presentation. The CAPE COD trial enrolled patients within 24 hours of ICU admission 2.
Drug selection: While various corticosteroids have been studied, hydrocortisone has the strongest mortality benefit in recent network meta-analysis 8. Prednisolone and methylprednisolone also show efficacy, but hydrocortisone demonstrated superior mortality reduction (RR 0.35) 9, 8.
Practical Implementation
For a patient admitted to ICU with severe bacterial CAP (excluding influenza):
- Start hydrocortisone 200 mg IV daily immediately
- Continue for 4-7 days based on clinical response (fever resolution, hemodynamic stability, oxygenation improvement)
- Taper over subsequent 4-7 days (total 8-14 days)
- Monitor blood glucose and treat hyperglycemia aggressively
- Continue appropriate antimicrobial therapy concurrently
This approach balances the moderate-certainty evidence for mortality benefit against the manageable risk of hyperglycemia in the severe CAP population most likely to benefit.